Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: water for injections; sodium citrate; citric acid monohydrate; sodium chloride - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Canada - English - Health Canada

sandoz canada incorporated - hydromorphone hydrochloride - solution - 2mg - hydromorphone hydrochloride 2mg - opiate agonists

Canada - English - Health Canada

sterimax inc - hydromorphone hydrochloride - solution - 2mg - hydromorphone hydrochloride 2mg - opiate agonists

Canada - English - Health Canada

fresenius kabi canada ltd - hydromorphone hydrochloride - solution - 2mg - hydromorphone hydrochloride 2mg - opiate agonists

Canada - English - Health Canada

jamp pharma corporation - hydromorphone hydrochloride - solution - 2mg - hydromorphone hydrochloride 2mg

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2 ) ],   reserve hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7)] - known or suspected gastrointe

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate; water for injections; sodium chloride; citric acid monohydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

United States - English - NLM (National Library of Medicine)

lannett company, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride oral solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2 )] , reserve hydromorphone hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride oral solution is contraindicated in patients with: - significant respiratory depression [see warnings and precautions ( 5.7 )] significant respiratory depression [see warnings and precautions ( 5.7 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautio